Frequently Asked Questions
The market is segmented based on , By Type (Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Others), Drugs (Heparin, Warfarin and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Thrombophilia Market size was valued at USD 15.95 USD Billion in 2022.
The Global Thrombophilia Market is projected to grow at a CAGR of 7% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer , F. Hoffmann, La Roche Ltd, Mylan N.V., Aspen Holdings, Changzhaou Qianhong Biopharma Co. , Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. , Hikma Pharmaceuticals PLC, Novartis AG, Shanghai Fosun Pharmaceutical Co. Ltd, Hepalink Group, Teva Pharmaceutical Industries , Yino Pharma Limited.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
